GlassScriptPhysician profile
Robert Earl Beck
NPI 1831458165
$1,773.00
in general payments reported to CMS, 2019-2025
30 companies · $1,308 in 2025
The $1,308 reported for 2025 was more than what 86% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.60 · 2020: $145 · 2021: $228 · 2022: $20.48 · 2025: $1,308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,307.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elekta, INC. | $216.86 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $209.02 | 2025 | |
| Exelixis INC. | $167.26 | 2025 | Cabometyx |
| Janssen Biotech, INC. | $116.11 | 2025 | Darzalex, Talvey, Rybrevant |
| Varian Medical Systems, INC. | $99.12 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $90.71 | 2025 | Imfinzi |
| Regeneron Healthcare Solutions, INC. | $89.07 | 2025 | Libtayo, Lynozyfic |
| Novocure INC. | $79.27 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $73.75 | 2025 | Keytruda, Keytruda Qlex, Lynparza |
| Genentech USA, INC. | $65.78 | 2025 | Tecentriq, Venclexta |
| Siemens Medical Solutions USA, INC. | $56.25 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $47.73 | 2025 | Opdivo, Opdualag |
| Lilly USA, LLC | $40.93 | 2025 | Verzenio, Jaypirca |
| Sumitomo Pharma America, INC. | $39.77 | 2025 | Orgovyx |
| Stemline Therapeutics INC. | $34.61 | 2025 | Orserdu |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $34.39 | 2025 | Pyrukynd |
| Karyopharm Therapeutics INC. | $33.25 | 2025 | Xpovio |
| Sobi, INC | $31.21 | 2025 | |
| Genzyme Corporation | $30.67 | 2025 | |
| Tempus Ai, INC | $29.79 | 2025 | Xt Cdx |
| Emd Serono, INC. | $24.10 | 2025 | |
| Puma Biotechnology, INC. | $21.20 | 2025 | |
| Astellas Pharma US INC | $20.40 | 2025 | Vyloy |
| Incyte Corporation | $19.62 | 2025 | Jakafi |
| Kyowa Kirin, INC. | $19.45 | 2025 | |
| Genmab U.S., INC. | $18.97 | 2025 | Epkinly |
| Takeda Pharmaceuticals U.S.A., INC. | $18.01 | 2025 | Fruzaqla |
| Dendreon Pharmaceuticals LLC | $16.99 | 2025 | Provenge |
| Caris Mpi, INC. | $14.94 | 2025 | Mi Cancer Seek |
| Blue Earth Diagnostics | $13.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Beck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.